Kidney Research UK in collaboration with Dr James Burton highlight the unmet needs in research, the urgency and importance of transforming treatments for people living with kidney disease.
Find out more at: https://www.kidneyresearchuk.
Support: Published in collaboration with Kidney Research UK.
Trending Topic
Finerenone (a selective nonsteroidal mineralocorticoid receptor antagonist) and the SGLT2 inhibitor empagliflozin may reduce both kidney and cardiovascular risks in people with chronic kidney disease and type 2 diabetes. It is unknown whether dual therapy with finerenone and empagliflozin is superior to either agent alone. In this touchENDOCRINOLOGY interview, Prof. Jennifer Green (Duke University School […]
There is a high unmet need for new treatments to preserve kidney function and delay kidney disease progression in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). In this touchENDOCRINOLOGY interview, Prof. Jennifer Green (Duke University School ...
SUSTAIN 6 and PIONEER 6 investigated the effects of semaglutide versus placebo on major adverse cardiovascular events (MACE). The current post hoc analysis investigated the association between baseline kidney function and risk of MACE, and the effect of semaglutide on risk of ...
Chronic kidney disease (CKD) is a common diabetes-related complication among type 2 diabetes (T2DM) patients, with a high prevelance within primary care settings. In this touchENDOCRINOLOGY interview, we speak with Dr Sara (Mandy) Reece (Philadelphia College of Osteopathic Medicine (PCOM), ...
The current treatment options for chronic kidney disease in patients with type 2 diabetes is discussed by Professor Hiddo Heerspink (University Medical Center Groningen, Groningen, Netherlands). Also discussed is the mechanism of tirzepatide, a novel once-weekly medication, which has shown to ...
A pre-specific exploratory analysis of SURPASS-4 evaluated the progression to pre-specified kidney endpoints between tirzepatide and titrated daily insulin glargine in chronic kidney disease. Professor Hiddo Heerspink (University Medical Center Groningen, Groningen, Netherlands) discusses the outcome of the analysis and ...
The combined use of finerenone and glucagon-like peptide-1 receptor agonist (GLP-1RA) for chronic kidney disease (CKD) and type 2 diabetes (T2D) was studied in the FIDELITY analysis, and is discussed by Professor Peter Rossing (Steno Diabetes Center, Copenhagen, Denmark). ...
Kidney Research UK in collaboration with Dr James Burton highlight the unmet needs in research, the urgency and importance of transforming treatments for people living with kidney disease. Find out more at: https://www.kidneyresearchuk.org/ Support: Published in collaboration ...
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
